Search Within

Jose T Baselga

  1. "Hematology-Oncology Fellows"
Formats
  1. Journal Article (29)
  2. Meeting Abstract (27)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. Department of Medicine (59)
  2. Hematology-Oncology Fellows (59)
  3. Solid Tumor Oncology Division (58)
  4. Breast Medicine Service (53)
  5. GSK Faculty (51)
  6. Weinberg Fellows (51)

More Groups

People
  1. Michael Berger (34)
  2. David Hyman (31)
  3. Pedram Razavi (31)
  4. David Solit (26)
  5. Sarat Chandarlapaty (26)
  6. Ahmet Zehir (25)

More People

Years
  1. 2021 (2)
  2. 2020 (7)
  3. 2019 (10)
  4. 2018 (14)
  5. 2017 (12)
  6. 2016 (7)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Cancer Research (9)
  3. Cancer Cell (5)
  4. Cancer Discovery (5)
  5. Modern Pathology (4)
  6. Nature (3)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (14)
  3. Nature Publishing Group (10)
  4. Cell Press (6)
  5. Nature Research (4)
  6. American Association for the Advancement of Science (2)

More Publishers

Results (59)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing of matched normal blood identifies clonal hematopoiesis in a significant subset of solid tumor patients without hematologic malignancies
    Meeting Abstract

    Coombs, C. C.; Zehir, A.; Devlin, S.; Middha, S.; Cheng, D.; Kishtagari, A.; Hyman, D. M.; Solit, D.; Robson, M.; Baselga, J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays
    Meeting Abstract

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Nafa, K.; Jour, G.; Razavi, P.; Hyman, D. M.; Baselga, J.; Berger, M. F.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Adaptive and acquired mechanisms of resistance to PI3K inhibitors
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Will, M.; Li, Z.; Bosch Campos, A.; Schwartz, S.; Rodrik-Outmezguine, V. ; Berger, M.; Baselga, J.; Rosen, N.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ
    Journal Article

    Schwartz, S.; Wongvipat, J.; Trigwell, C. B.; Hancox, U.; Carver, B. S.; Rodrik-Outmezguine, V. ; Will, M.; Yellen, P.; de Stanchina, E.; Baselga, J.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
    Journal Article

    Will, M.; Qin, A. C. R.; Toy, W.; Yao, Z.; Rodrik-Outmezguine, V. ; Schneider, C.; Huang, X.; Monian, P.; Jiang, X.; de Stanchina, E.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling
    Meeting Abstract

    Will, M.; Toy, W.; Yao, Z.; Poulikakos, P.; Rodrik-Outmezguine, V. ; Schneider, C.; Paul, J.; Baselga, J.; Liu, N.; Rosen, N.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A mechanistic logic for dual targeting of HER2 and PI3K/AKT/mTOR signaling in HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Rodrik-Outmezguine, V.; Scaltriti, M. M.; Sakr, R.; Will, M.; Giri, D.; Hudis, C.; Baselga, J.; King, T.; Rosen, N.
    European Journal of Cancer (2012)

    Fulltext@MSK | Save